Atossa Genetics Inc (ATOS.OQ)
ATOS.OQ on NASDAQ Stock Exchange Capital Market
1.63USD
25 Sep 2018
1.63USD
25 Sep 2018
Change (% chg)
$-0.07 (-4.12%)
$-0.07 (-4.12%)
Prev Close
$1.70
$1.70
Open
$1.72
$1.72
Day's High
$1.74
$1.74
Day's Low
$1.63
$1.63
Volume
19,646
19,646
Avg. Vol
34,649
34,649
52-wk High
$18.96
$18.96
52-wk Low
$1.41
$1.41
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Steven Quay |
64 | Chairman of the Board, President, Chief Executive Officer | |
Kyle Guse |
51 | 2013 | Chief Financial Officer, General Counsel, Secretary |
Cindy Atha |
2015 | Vice President of Sales and Marketing | |
Janet Rea |
2015 | Vice President - Regulatory Affairs and Quality | |
Shu-Chih Chen |
53 | 2014 | Director |
- BRIEF-Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study
- BRIEF-Intracoastal Capital Reports 5.9 Pct passive Stake In Atossa Genetics Inc, As Of April 23, 2018
- BRIEF-Atossa Genetics Receives Positive Interim Review From Independent Safety Committee In Phase 1 Topical Endoxifen Dose Escalation Study In Men
- BRIEF-Atossa Genetics Announces 1 For 12 Reverse Stock Split